Newton Charles W.
SEC-identified person · CIK 1866219 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Novavax INC nvax | Director | filed 2025 - 2026 |
| Keros Therapeutics, Inc. KROS | Director | filed 2026 - 2026 |
| Coherus Oncology, Inc. CHRS | Director | filed 2022 - 2026 |
| Lyell Immunopharma, Inc. LYEL | Chief Financial Officer | filed 2021 - 2025 |
| 2Seventy bio, Inc. TSVT | Director | filed 2024 - 2025 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.